AIIMS Develops Affordable CAR-T Cell Therapy for Multiple Myeloma

Sangamo Therapeutics and Astellas Collaborate on Innovative Gene Therapy for Neurological Diseases

FDA Clears IND for Arbor Biotechnologies’ ABO-101 Gene Editing Therapeutic for Primary Hyperoxaluria Type 1

Fortis Healthcare Acquires Stake in Agilus Diagnostics

FDA Approves BRAFTOVI® Combination Regimen as First-Line Treatment for BRAF V600E-Mutant Metastatic Colorectal Cancer

The Role of Big Data in Precision Medicine

Caris Life Sciences Celebrates 1,000+ Precision Medicine Studies, Advancing Cancer Research and Patient Outcomes

OncoHelix and Qualisure Diagnostics Partner to Bring Thyroid GuidePx® Test to Canadian Patients

Gates Foundation Invests $50 Million in Tessera Therapeutics to Advance Gene Therapy for Sickle Cell Disease

FDA Approves Ensartinib (Ensacove) as First-Line Treatment for ALK-Positive NSCLC

Guardant Health and Boehringer Ingelheim Collaborate to Advance Liquid Biopsy CDx for HER2-Targeted Therapy in NSCLC

Cartherics Receives $300K G-Rex Grant to Advance Cancer Cell Therapy Manufacturing

Roche Revolutionizes Mass Spectrometry Diagnostics with Launch of cobas® Mass Spec Solution

Complete Genomics Partners with Eurofins Clinical Enterprise to Expand Sequencing Service Offerings

NeuroKaire Secures $10M to Transform Precision Medicine in Psychiatry and Neurology

Home
/
update
/
details

QIAGEN and Illumina Unveil New Solutions to Advance Liquid Biopsy and Next-Generation Sequencing

NextEdge Admin

15 Oct 2024

3 min 13 sec

QIAGEN Introduces Key Enhancements to Liquid Biopsy Technologies for Advanced Biomarker Detection

QIAGEN has announced key updates to its sample technologies for non-invasive liquid biopsy applications in fields such as oncology, prenatal care, and organ transplantation. These enhancements include upgraded kits and platforms designed to improve biomarker detection through higher yields of circulating cell-free DNA (ccfDNA).

The enhanced EZ1&2 ccfDNA Kit now supports fully automated processing of 24 samples with up to 10 mL of serum or plasma, alongside a new urine protocol, addressing the need for larger sample inputs essential for low-frequency mutation detection. Additionally, the QIAsymphony DSP Circulating DNA Kits—available in standard and high-throughput versions—offer flexible solutions for labs of varying sizes, ensuring compliance with CE-IVDR and FDA regulations.

These updates expand QIAGEN’s automated solutions portfolio, enabling laboratories to perform high-sensitivity downstream analyses such as NGS, dPCR, and real-time PCR. Complementing these advancements is the new PAXgene Urine Liquid Biopsy Set, enhancing cfDNA analysis from urine samples.

Illumina Launches MiSeq™ i100 Series to Accelerate and Simplify Next-Generation Sequencing

Illumina, has introduced the MiSeq™ i100 Series, featuring the MiSeq i100 and MiSeq i100 Plus Systems, designed to simplify and accelerate next-generation sequencing (NGS) for labs. These benchtop instruments offer easy operation, room-temperature reagent storage, and same-day sample-to-analysis, making NGS more accessible, even for users with limited expertise.

The MiSeq i100 Series builds on the original MiSeq platform while incorporating advanced XLEAP-SBS™ chemistry and technology from the NovaSeq™ X Series. It offers two configurations: the i100 Plus with 100 million reads per run and the i100 with 25 million reads per run. Key features include faster run times (as short as four hours), reduced packaging waste by 85%, and cost-effective consumables.

Push-button workflows support applications like microbiology, oncology, and infectious disease, with real-time metrics available on the instrument or via cloud-based DRAGEN™ analysis. This compact, sustainable system delivers the speed, scalability, and ease required to advance genomic research.